ProteoNic Biosciences launches platform to enhance cell line productivity
Ella Day | September 17, 2025 | News story | Research and Development | Devices, ProteoNic Biosciences, cell line productivity, gene therapy
ProteoNic Biosciences, a biotech company headquartered in Leiden, Germany has unveiled its latest technology platform, the 2G UNic transposon system, developed for applications in protein production and gene therapy.
The new platform builds on ProteoNic 2G UNic vector technology by incorporating a proprietary transposable element (transposon) system. Transposons are nucleic acid sequences capable of moving within a genome and occur naturally in both animal and plant cells.
The platform is applicable to both mammalian and yeast cell systems. The company reports that it enables more efficient expression of advanced biologics, including proteins that are typically difficult to produce at scale.
It is designed for broad use across biopharma development, spanning therapeutic antibody and protein manufacturing, as well as the generation of stable producer cell lines for cell and gene therapy applications.
“We are proud to announce the development and launch of our 2G UNic transposon platform, which elevates productivity, flexibility and ease of use in cell line generation,” said Frank Pieper, CEO of ProteoNic Biosciences.
In parallel, ProteoNic has expanded the functionality of its 2G UNic vector technology to support third-party transposon systems, allowing customers to integrate the technology into existing processes.
Following its presentation at BioProcess International 2025, both the transposon platform and the expanded 2G UNic vector technology will become commercially available. ProteoNic noted that both systems have already undergone successful evaluations with industry partners.
Charlie Blackie-Kelly
17/9/25
Related Content
Sartorius Stedim Biotech partners with Nanotein Technologies to develop cell therapy manufacturing
Sartorius Stedim Biotech has partnered with Nanotein Technologies to expand access to immune cell activation …
Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes
Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec …
Terumo BCT showcases new CAR-T workflow enabling faster cell expansion
Terumo Blood and Cell Technologies (Terumo BCT) has unveiled a new automated workflow that consolidates …
